We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Circassia Group Plc | CIR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 34.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 34.00 | 34.00 |
| Top Posts |
|---|
Posted at 13/9/2022 06:30 by p1nkfish Interesting capital reduction proposal.Can see more of a buyback chance than special dividend. |
Posted at 12/5/2022 07:33 by drdre I have been watching CIR a while and impressed by recent newsflow. Whats the target addressable market they are in? |
Posted at 10/2/2022 16:28 by masurenguy Took an opening position in CIR earlier today. |
Posted at 13/1/2022 11:29 by apad CIR is commented on in this morning's SCVR.apad |
Posted at 12/1/2022 14:47 by masurenguy Re post #1057 - CIR was tipped this morning. |
Posted at 24/12/2021 10:28 by someuwin One way or another CIR should be a big winner in 2022. |
Posted at 24/9/2021 07:08 by tomps2 Christopher Mills mentions Circassia (CIR) at 08:03 in the latest PIWORLD InterviewWatch the video here: Or listen to the podcast here: |
Posted at 21/9/2021 15:13 by hammergaumet Found an interesting twitter account writing up ideas that have supportive insider buying. CIR circassia is recently covered!https://twit |
Posted at 06/8/2021 12:58 by thelongandtheshortandthetall Haha. I'll be excited when CIR is 62p - Namely when the new directors get their bonuses. |
Posted at 09/4/2020 06:06 by pro_s2009 Proposed transfer of assets to and termination of agreement with AstraZeneca for consideration to be set off against debt and accrued interestOxford, UK - 9 April 2020 Circassia Pharmaceuticals plc, ("Circassia" or "the Company"; LSE: CIR) announces that the Board has concluded that it is in the best interests of the Company to terminate the development and commercialisation agreement between the Company and AstraZeneca UK Limited, a subsidiary of AstraZeneca plc (LSE/STO/NYSE: AZN) (AstraZeneca) for the U.S. commercial rights to Tudorza(R) and Duaklir(R) and transfer the assets to AstraZeneca (the Transaction). On completion of the Transaction, AstraZeneca will acquire the U.S. commercial rights to Tudorza(R) and Duaklir(R) together with certain ancillary rights and assets, from Circassia the consideration for which shall be equal to, and shall be satisfied by way of set-off against, the entirety of the loan amount outstanding from the Company to AstraZeneca, together with accrued interest owed by the Company to AstraZeneca, as at the date of completion of the Transaction (being approximately US$149.9 million as at the date of announcement) AstraZeneca will retain its 18.9% shareholding in the Company. Subject to receipt of necessary approvals, it is anticipated that the Transaction will complete in no longer than three months. The proposed Transaction will constitute a fundamental change of business of Circassia under Rule 15 of the AIM Rules for Companies and is therefore conditional on, inter alia, the passing of an ordinary resolution to approve the Transaction at the General Meeting, a circular convening the General Meeting is expected to be posted to Shareholders shortly. In addition, the Transaction is considered to constitute a related party transaction under Rule 13 of the AIM Rules for Companies. On completion of the Transaction, Circassia proposes to change its name to Circassia Group plc, subject to the passing of a special resolution to approve the Company's change of name at the General Meeting. Ian Johnson, Circassia's Executive Chairman, said: "As a Board and Management team, we conducted a strategic review of our business and its prospects, concluding that it would be in the best interests of both patients and our shareholders for us to terminate the development and commercialisation agreement between the Company and AstraZeneca UK Limited for the U.S. commercial rights to Tudorza(R) and Duaklir(R). As we look to move forwards with a primary focus on our Niox(R) respiratory diagnostic platform, we are confident in our ability to drive long-term growth. Upon completion, this transaction will transform Circassia into a debt-free business with a strong revenue-generating business, with which we have the potential to expand into new territories and a commercial infrastructure that can in the medium term be further leveraged through broadening its range of products. This fundamental change in the business will place us in a strong position to deliver improved shareholder value." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
